Filings & reports

 


Company analysis (paid / non-paid):

Nov 2019 – Affarsvalden_Cessatech (non-paid)


Rights issue transaction:

221118 – Last day of trading in Cessatech BTUs
221114 – Outcome of Cessatech rights issue
221108 – Subscription period ends in Cessatech rights issue
221027 – Cessatech Subscription form – without rights
221027 – Subscription period starts in Cessatech rights issue
221027 – Cessatech AS – KID Document
221020 – Extraordinary general meeting (compensation and increase share capital)
221020 – Rigts issue, Marketing brochure
221020 – Cessatech Rights Issue memorandum
221020 – Cessatech publishes offering memorandum
221019 – Cessatech announcement of Rights issue


Press releases:

221118 – Last day of trading in Cessatech BTUs
221118 – Cessatech_Q3-2022 Report
221114 – Outcome of Cessatech rights issue
221108 – Subscription period ends in Cessatech rights issue
221104 – Extraordinary general meeting minutes
221027 – Subscription period starts in Cessatech rights issue
221020 – Cessatech – Notice to EGM
221020 – Cessatech publishes offering memorandum
221019 – Announcement of Rights issue
220923 – TopLine Results of trial 0206
220905 – First patient dosed trial 0205
220819 – Cessatech_Q2-2022 Report
220630 – Regulatory green light trial0205
220516 – Last patient in trial 0206
220419 – Cessatech_Q1-2022 Report
220317 – AnnualGeneral Meeting 2022_Minutes
220308 – trial 0204 successful topline results
220303 – Annual Report 2021
220302 – Cessatech_AnnualGeneralMeeting_2021_Agenda
220224 – Cessatech_Q4-2021_Report
220222 – Trial 0204 results expected soon
220106 – Changes to the Board of Directors
220104 – Warrant exercise registered

211222 – Cessatech successfully raises approx. DKK 24.3 million through warrant exercise
211214 – Last day of trading_CT warrants of series TO 1
211208 – BoD and CEO exercise their TO 1 warrants
211125 – Exercise period for Warrants TO 1
211119 – Cessatech_Q3-2021 Report
211102 – US patent issuance
210820 – First patient in trial 0206…
210819 – Cessatech_Q2-2021 Report
210629 – NewChairman of the Board
210531 – Last subject dosed trial 0204
210514 – IPO of the year 2020
210419 – Cessatech_Q1-2021 Report
212603 – Minutes_Annual General Meeting 2021
210324 – First subject dosed trial 0204_
210311 – Annual Report Release 2020
210310 – Annual General Meeting 2021
210309 – Best Medical Treatment IPO Nordics Award – CFI.co
210304 – Favourable data from the Registry Safety Study
210211 – Year-end report Q4-2020

201215 – Invitation to listing ceremony
201214 – Grant of incentive warrants
201127 – Significantly oversubscribed IPO
201110 – The subscription period in the IPO commences
201106 – Approval for listing and publishes prospectus


Newsletters:

221010 – Newsletter #8 Oct2022
220811 – Newsletter#7 Aug2022
220331 – Newsletter#6_Mar2022_English
220331 – Newsletter#6_Mar2022_Swedish
213012 – Newsletter#5_Dec 2021
211112 – Newsletter#4_Nov 2021
210630 – Newsletter#3_Jun 2021
210331 – Newsletter#2_Mar 2021
210128 – Newsletter#1_Jan 2021

 


Download the Financial Statements:

CT_Q3-2022 Report
CT_Q2-2022 Report
CT_Q1-2022 Report
CT_ANNUAL REPORT 2021
CT_Q4-2021 Report
CT_Q3-2021 Report
CT_Q2-2021 Report
CT_Q1-2021 Report
CT_ANNUAL REPORT 2020
CT_Q4-2020 Year-end Report
Interim_Financial_Statement_31_August_2020


Download the Teaser:

Cessatech_teaser_final


Download the Prospectus:

Cessatech AS – IPO Prospectus 2020 – final
Särskild sammanfattning i EU-tillväxtprospekt


 

Stay up to date!

Subscribe and get notified on Cessatech's latest news.